agilon health (AGL) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $2.15
- Estimate
- $0.27
- Surprise
- +691.5%
- Revenue (period 2026-06-30)
- $1.49B
- Score today
- 5.7/10
Revenue source: xbrl.
How the report landed
agilon health (AGL) beat the $0.27 estimate with adjusted EPS of $2.15 — a large 691.5% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates AGL Sell at 5.7/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +691.5% surprise compares with a +180.0% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Target reached (-11.4% upside)
- Quality below floor (1.6 < 4.0)
- Negative risk/reward — downside exceeds upside
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $113.77
- Stop
- $105.81
Risk check: RSI 82 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 2.8× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
AGL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Care Facilities
- Market cap
- $1.62B
- P/E (fwd)
- 40.8
- 52-week range
- $7.48–$133.04
- Off 52-week high
- 14.5%
- RSI (14)
- 82
- Volume vs avg
- 2.77×
- Score today
- 5.7/10